Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treprostinil Palmitil Inhalation Powder in Pulmonary Arterial Hypertension
NCT05147805Phase 2Completed
- Sponsor
- Insmed Incorporated
- Start
- Aug 2022
- Primary completion
- Mar 2025
- Modality
- Inhalation Devices, Prodrugs/Conditional Activator Small Molecules
- Countries
- 17
01
Overview
Phase 2, randomised, double-blind trial in pulmonary arterial hypertension (PAH) comparing Treprostinil Palmitil Inhalation Powder with Placebo (2 arms). Primary endpoint: Pulmonary Vascular Resistance at 16 weeks. Started Aug 2022; status: completed.
02
Drugs
treprostinil palmitil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT05147805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05147805.